Cencora Stock: Analyst Estimates & Ratings
/Cencora%20Inc_%20HQ-by%20JHVEPhoto%20via%20iStock.jpg)
Valued at a market cap of $56 billion, Cencora, Inc. (COR) sources and distributes pharmaceutical products for people and animals. The Conshohocken, Pennsylvania-based company provides essential support, encompassing clinical trial logistics and consulting to packaging, data analytics, and patient adherence programs.
This healthcare company has outpaced the broader market over the past 52 weeks. Shares of COR have surged 21.6% over this time frame, while the broader S&P 500 Index ($SPX) has gained 20.6%. Moreover, on a YTD basis, the stock is up 28.7%, compared to SPX’s 9.6% return.
Zooming in further, COR’s outperformance looks even more pronounced when compared to the VanEck Pharmaceutical ETF’s (PPH) 11% loss over the past 52 weeks and 3.2% YTD drop.
On Aug. 6, Cencora released its Q3 results. Due to growth in both its U.S. and International healthcare solutions segments, the company’s overall revenue improved 8.7% year-over-year to $80.7 billion, surpassing consensus estimates by a slight margin. Moreover, its adjusted EPS of $4 advanced 19.8% from the prior-year quarter and came in 5.8% above analyst expectations. Additionally, COR raised its fiscal 2025 adjusted EPS guidance, and now expects it to be between $15.85 and $16. Yet, its shares tumbled 2.9% after the earnings release.
For the current fiscal year, ending in September, analysts expect COR’s EPS to grow 15.9% year over year to $15.95. The company’s earnings surprise history is promising. It surpassed the consensus estimates in each of the last four quarters.
Among the 14 analysts covering the stock, the consensus rating is a "Strong Buy” which is based on 11 “Strong Buy,” and three “Hold” ratings.
This configuration is slightly more bullish than three months ago, with 10 analysts suggesting a “Strong Buy” rating.
On Aug. 11, JPMorgan Chase & Co. (JPM) analyst Richard Choe maintained a "Buy" rating on COR and set a price target of $344, implying a 19% potential upside from the current levels.
The mean price target of $335 represents a 15.9% premium from COR’s current price levels, while the Street-high price target of $355 suggests an ambitious upside potential of 22.8%.
On the date of publication, Neharika Jain did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.